Table 1.
Patient characteristics before starting and after targeted therapy (BRAF mutant), and before starting and after ipilimumab (BRAF wild-type).
| BRAF mutated (n=16) |
BRAF wild-type (n=26) |
|||
| Characteristic |
Before target therapy |
After target therapy |
Before ipilimumab |
After ipilimumab |
| LDH levels | ||||
| Elevated (> 2) | 3 | 1 | 2 | 3 |
| Elevated ( >1 and ≤ 2) | 3 | 9 | 11 | 11 |
| Normal | 10 | 6 | 13 | 12 |
| Visceral sites | ||||
| ≥ 3 sites | 12 | 12 | 11 | 8 |
| < 3 sites | 4 | 4 | 15 | 18 |
| Performance status | ||||
| 0 | 11 | 3 | 14 | 11 |
| 1 | 5 | 13 | 12 | 15 |
| Targeted therapy | ||||
| Vemurafenib | 14 | NA | NA | NA |
| MEK inhibitor | 2 | |||
| Previous line of treatment | ||||
| 0 | 15 | NA | 4 | NA |
| 1 | 1 | 22 | ||
| Previous treatments | ||||
| Dacarbazine | 0 | NA | 21 | NA |
| Temozolomide | 0 | 1 | ||
| MEK inhibitor | 0 | 0 | ||
| Ipilimumab | 1 | 0 | ||